Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Tokyo, May 28, 2013 (JCN Newswire) - Eisai Co., Ltd. announced today that it will launch antiepileptic agent Inovelon(R) Tablets 100 mg and 200 mg (rufinamide) in Japan on May 29 as an adjunctive therapy to other antiepileptic drugs (AEDs) in the treatment of Lennox-Gastaut syndrome (LGS). The agent was designated by the Japanese Ministry of Health, Labour and Welfare (MHLW) as an orphan drug in June 2011; it received Japan manufacturing and marketing authorization on March 25, 2013, and was placed on the country's National Health Insurance (NHI) drug price list on May 24 of the same year.
Help employers find you! Check out all the jobs and post your resume.
Tokyo, May 28, 2013 (JCN Newswire) - Eisai Co., Ltd. announced today that it will launch antiepileptic agent Inovelon(R) Tablets 100 mg and 200 mg (rufinamide) in Japan on May 29 as an adjunctive therapy to other antiepileptic drugs (AEDs) in the treatment of Lennox-Gastaut syndrome (LGS). The agent was designated by the Japanese Ministry of Health, Labour and Welfare (MHLW) as an orphan drug in June 2011; it received Japan manufacturing and marketing authorization on March 25, 2013, and was placed on the country's National Health Insurance (NHI) drug price list on May 24 of the same year.
Help employers find you! Check out all the jobs and post your resume.
